Pantocid Tablet belongs to a class of medicines known as proton pump inhibitors (PPIs). It is primarily used to reduce the ...
Since their development and widespread adoption in the late 1980s, proton pump inhibitors (PPI) have transformed the field of gastroenterology. Their high efficacy and favorable safety profiles have ...
Nearly 70% of patients with acute upper gastrointestinal (GI) bleeding and low-risk or no peptic ulcer disease received intravenous (IV) proton pump inhibitors (PPIs) inappropriately, leading to ...
Please provide your email address to receive an email when new articles are posted on . An intervention program was associated with an absolute reduction of 7.3% in patients who filled proton pump ...
Long-term use of proton pump inhibitors (PPIs) did not appear to be associated with an increased risk of gastric cancer, according to a population-based case-control study in five Nordic countries.
Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems. PPIs are activated in the acid-producing cells of the ...
Accelerating phase 2 clinical development with real-world data (RWD): An external control arm (ECA) pilot in HER2-positive (HER2+) metastatic breast cancer (mBC). This is an ASCO Meeting Abstract from ...
The use of proton pump inhibitors with anti-cancer therapies was associated with worse survival outcomes in patients with breast cancer. Concomitant use of proton pump inhibitors and other everyday ...
The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased risk of developing gastric (stomach) cancer, finds ...
The potential link between use of proton pump inhibitors and gastric cancer has been an ongoing controversial subject since the drugs entered the market in the late 1980s. Long-term use of proton pump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results